MOUNTAIN VIEW, Calif., May 7 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced financial results for the first quarter ended March 31, 2009.
The net loss for the first quarter ended March 31, 2009 was $9.9 million compared to $14.3 million during the same period in 2008.
Revenue for the first quarter ended March 31, 2009 was $7.5 million compared to $0 for the same period in 2008. The increase in revenue for the first quarter of 2009 was due to amortization of a $40.0 million upfront payment received in February 2009 and reimbursements for Unit Dose Budesonide (UDB) related development expenses, pursuant to MAP Pharmaceuticals’ license agreement with AstraZeneca.
Research and development expenses for the first quarter ended March 31, 2009 were $14.1 million compared to $11.8 million for the same period in 2008. The increase in research and development expenses for the first quarter of 2009 was driven primarily by an increase in clinical and personnel related expenses to support Phase 3 clinical programs for MAP Pharmaceuticals’ two lead product candidates, UDB and MAP0004, for the potential treatment of pediatric asthma and migraine, respectively.
Sales, general and administrative expenses for the first quarter ended March 31, 2009 were $2.8 million compared to $3.1 million for the same period in 2008. The decrease in sales, general and administrative expenses for the first quarter of 2009 was related primarily to decreases in professional fees and other miscellaneous fees, partially offset by an increase in stock-based compensation.
MAP Pharmaceuticals had cash, cash equivalents and short-term investments as of March 31, 2009 of $67.7 million, compared to $44.7 million as of December 31, 2008. In addition, accounts receivables were $4.7 million at March 31, 2009, compared to $0 at December 31, 2008, due to the collaboration with AstraZeneca.
For the first quarter ended March 31, 2009, non-cash share-based compensation and depreciation were approximately $1.6 million.
“We continue to work diligently to report the results of the efficacy portion of our first Phase 3 clinical trial evaluating MAP0004 during the first half of 2009, while also carefully managing our financial resources,” said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. “With our partner AstraZeneca, we continue to evaluate next steps for UDB clinical development.”
About MAP Pharmaceuticals
MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
Forward-Looking Statements
In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals’ late stage clinical programs. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company’s business, including, without limitation, risks and uncertainties relating to the following: the enrollment, conduct, completion and reporting of clinical trials as well as risks related to the failure to achieve favorable clinical outcomes and the risk that AstraZeneca may not continue its collaboration with MAP Pharmaceuticals. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals’ results and other risks and uncertainties are detailed in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended and available at http://edgar.sec.gov.
CONTACT: Christopher Y. Chai, Chief Financial Officer of MAP
Pharmaceuticals, Inc., +1-650-386-3107; or media, Gregory Gin of Invigorate
Communications, +1-908-376-7737, ggin@invigoratepr.com, for MAP
Pharmaceuticals, Inc.
Web site: http://www.mappharma.com/
